MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
NBRV - Nabriva Therapeutics Plc
$1.92
-0.47(-19.67%)12:17:11 AM 3/2/2021
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Price Zscore is at a recent 2 week low. A recent low ZScore means price drop is accelerating at a record speed.
  • Volume Zscore is a recent 2 week high. A recent surge of ZScore means trading activities is accelerating at a record speed.
  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
MarketCap28.9M
PE Ratio
PEG Ratio-0.0
P/B1.0
P/S (ttm)17.4
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %6%
Held by Institutions %21%
1 Day Vol Adjusted Return-3.2
1 Month Vol Adjusted Return-4.9
3 Month Vol Adjusted Return3.5
6 Month Vol Adjusted Return2.1
20 Days SMA Price ZScore-2.7
50 Days SMA Price ZScore-3.0
12 -26 Days PPO-4.5
1 Month Average Short Volume Ratio36.7
1 Day Volume Change ZScore4.3
1 Month Daily Vol6.1
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    03/1/2021NBRV
    Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement with certain healthcare-focused and institutional investors for the purchase and sale of (i) an aggregate of 10,361,010 ordinary shares (or pre-funded warrants in lieu thereof)...

    02/26/2021NBRV
    Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of Daniel Dolan as Chief Financial Officer (CFO), effective close of business March 12, 2021. Mr. Dolan will replace current CFO Gary Sender, who is retiring from Nabriva. Mr. Sender will serve as a consultant...

    02/17/2021NBRV
    UTILITY Therapeutics Joins Antimicrobials Working Group

    The Antimicrobials Working Group (AWG) announced today the addition of UTILITY therapeutics Ltd. (UTILITY) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 13 antimicrobial drug companies.

    02/2/2021NBRV
    The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 1) Abbott Laboratories (NYSE: ABT) Adamas Pharmaceuticals Inc (NASDAQ: ADMS) (announced FDA approval for an expanded indication for its Parkinson's drug) argenx SE – ADR (NASDAQ: ARGX) (announced decision to proceed with the enrollment into the study of subcutaneous efgartigimod in chronic inflammatory demyelinating polyneuropathy) BioCryst Pharmaceutical...

    02/1/2021NBRV
    Nabriva Therapeutics Announces Retirement of its Chief Financial Officer

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary Sender as Chief Financial Officer (CFO), effective as of March 12, 2021. Mr. Sender has agreed to serve as a consultant for Nabriva on an ongoing basis following his retirement to ensure business contin...

    01/5/2021NBRV
    Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences in January

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming investor conferences in January. * H.C. Wainwright BioConnect Conference being held virtually from January 11-14, 2021. Ted Schroeder, Chief Executive Officer at Nabriva, wi...